PROF

Profound Medical

4.99 USD
+0.10
2.04%
At close Apr 30, 4:00 PM EDT
After hours
4.99
+0.00
0.00%
1 day
2.04%
5 days
6.17%
1 month
-14.26%
3 months
-22.15%
6 months
-33.02%
Year to date
-36.84%
1 year
-32.93%
5 years
-62.95%
10 years
-49.49%
 

About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Employees: 142

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

164% more call options, than puts

Call options by funds: $29K | Put options by funds: $11K

37% more capital invested

Capital invested by funds: $75M [Q3] → $103M (+$28.1M) [Q4]

18% more funds holding

Funds holding: 44 [Q3] → 52 (+8) [Q4]

7.4% more ownership

Funds ownership: 38.47% [Q3] → 45.86% (+7.4%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
120%
upside
Avg. target
$11
120%
upside
High target
$11
120%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Lake Street
Benjamin Haynor
0% 1-year accuracy
0 / 2 met price target
120%upside
$11
Buy
Maintained
23 Apr 2025

Financial journalist opinion

Based on 33 articles about PROF published over the past 30 days

Neutral
GlobeNewsWire
6 hours ago
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Neutral
Accesswire
10 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
1 day ago
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative results were presented yesterday by Xiaosong Meng, M.D.
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
Accesswire
6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
GlobeNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Neutral
Accesswire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Charts implemented using Lightweight Charts™